


SACCO
system



microbiome



**Active Ingredients
and Services**

Resources

6,500+

Cell bank
proprietary
strains

45+

Probiotic species
manufactured

40,000L

Up to 40'000L
fermentation
capacity

3

Pilot plant
up to 200L

90

Years of probiotic
manufacturing

50+


University
Partnerships

110

Export
Countries

8

Production
Plants



Active Ingredients

CultureScience

Our CultureScience portfolio presents a selection of clinically studied strains, strategically formulated to address various essential health concerns across different life stages. Available as individual strains or pre-formulated blends, each product has undergone thorough evaluation in gold-standard human clinical trials, confirming its proven health benefits.

We adhere to the highest quality standards in the manufacturing of CultureScience strains, ensuring their sustained activity and viability throughout the entire shelf life of your finished product. Our commitment to quality reflects our dedication to providing reliable and effective solutions for the well-being of end-users.



CultureSelect

Our CultureSelect portfolio offers a large selection of well-characterized strains with proven safety and produced under the highest quality standards to support your needs. CultureSelect strains provide a flexible solution to help you create unique formulations, with every product available as a single strain ingredient or a customized blend.



Gastrointestinal (GI) Health

Irritable Bowel Syndrome	PENTABIOCEL®	Reduces the severity of IBS-type symptoms in coeliac disease patients on a strict gluten free diet by improving gliadin hydrolysis (gluten protein mainly involved in the allergic burden).	20 Bn CFU/day
Microbiota Balance	SYNBIO®	Successfully colonizes the gut, competing with and reducing harmful bacteria as well as enhancing bowel habits and well-being.	1 Bn CFU/day
	<i>L. paracasei</i> NTU 101	Improves gut motility, decreases food transit time, significantly raises antibody levels and increases antioxidant activity.	5 Bn CFU/day
Diarrhoea	CRL 1505™	Significantly decreases intestinal infections. CRL 1505™ reduces acute diarrhoea and the use of antibiotics in children.	0,1 Bn CFU/day
<i>Helicobacter pylori</i> infection	<i>L. fermentum</i> UCO-979C	Reduces pathogen's colonization within the gut, preventing infection and stimulating the immune system.	0,3 Bn CFU/day

Skin Health

Acne	<i>L. rhamnosus</i> SP 1	Improves the appearance of acne and lessens the inflammatory processes related to acne formation by modulating genes involved in insulin signaling.	3 Bn CFU/day
Atopic Dermatitis	<i>L. rhamnosus</i> LB21	Significantly reduces the need to use corticosteroids in children.	100 Bn CFU/day
	<i>L. rhamnosus</i> LB21 + <i>L. rhamnosus</i> SP 1	Topical application decreases severity of visual signs and decreases intensity of itching in people with atopic dermatitis.	1 Bn CFU/day

Children & Infant Health

Respiratory and Diarrhoea	CRL 1505™	Significantly reduces upper respiratory tract infections, pharyngitis, tonsillitis, acute diarrhoea and the use of antibiotics .	0,1 Bn CFU/day
Infant Colic	<i>L. reuteri</i> LR 92	Maternal prenatal supplementation during the last 4 weeks of pregnancy reduces the incidence and severity of infant colic in newborn babies.	0,1 Bn CFU/day

Allergy

Dust-Mite Allergy	SYNBIO®	Significantly reduces allergy sensitization to house dust mites.	15 Bn CFU/day
-------------------	---------	--	---------------

Metabolic Health

Weight Management	IMC 510®	Significantly reduces body weight, waist circumference and BMI in subject free of any diet restriction. IMC510 effects continues for 30 days after supplementation.	15 Bn CFU/day
-------------------	----------	---	---------------

Oral Health

Dental Caries	<i>L. rhamnosus</i> SP 1	Regular intake reduces the occurrence of caries.	0,02-2 Bn CFU/day
	<i>L. rhamnosus</i> LB21	Reduces the development of caries and the number of days with antibiotic treatment by 60% in preschool children.	1,5 Bn CFU/day
	<i>B. coagulans</i> SNZ 1969	Significantly reduction of the cariogenic microorganism <i>Streptococcus mutans</i> in children.	0,15 Bn CFU/day
Aphthous Ulceration	<i>B. coagulans</i> SNZ 1969	Significantly reduces the incidence of recurrent aphthous (mouth) ulcers.	0,12 Bn CFU/day

Immune Health

Upper Respiratory Tract	CRL 1505™	Decreases the severity of upper respiratory tract infection symptoms as well as decreasing the overall duration of the infection.	0,1 Bn CFU/day
	SYNBIO®	Decreases severity of symptoms from upper respiratory tract infections.	1 Bn CFU/day

Women's Health

Bacterial Vaginosis	SYNBIO®	Improves symptoms associated with bacterial vaginosis (BV) while decreasing the chances of recurrence by restoring vaginal microbiota balance.	5 Bn CFU/day
Vaginal Dysbiosis	ProBioEtna CA 15®	Restores a healthy vaginal microbiota after 10 days of treatment, reducing Vulvovaginal Candidiasis (VVC) and Bacterial Vaginosis (BV). Also helps to balance the vaginal microbiota.	10 Bn CFU/day

Mental Health

Stress/Anxiety	<i>L. plantarum</i> P8	Reduces stress and anxiety, through multiple mechanisms of action, improving memory and cognitive functions.	20 Bn CFU/day
----------------	------------------------	--	---------------

Healthy Ageing

Inflammaging/Sarcopenia	SYNBIO®	Supports healthy ageing by reducing chronic low-grade inflammation associated with age-related pathologies. May also reduce the risk of sarcopenia.	5 Bn CFU/day
-------------------------	---------	---	--------------

Sport

Performance Improvement	SYNBIO®	Improves the body's recovery processes and tiredness sensation after training by lowering exercise-induced oxidative stress. In addition, SYNBIO® improves gastrointestinal functions and reduce susceptibility to illness.	1 Bn CFU/day
-------------------------	---------	---	--------------

Species	Strain name	Concentration (Billion CFU/g)*
<i>Bifidobacterium animalis subsp. lactis</i>	Bi1	300
<i>Bifidobacterium animalis subsp. lactis</i>	BLC1	500
<i>Bifidobacterium bifidum</i>	SP 9	100
<i>Bifidobacterium breve</i>	Bbr8	300
<i>Bifidobacterium breve</i>	BL10	200
<i>Bifidobacterium infantis</i>	SP 37	100
<i>Bifidobacterium longum</i>	SP 54	100
<i>Enterococcus faecium</i>	SF68	300
<i>Lactobacillus acidophilus</i>	LA3	200
<i>Lactobacillus acidophilus</i>	LA1	200
<i>Lactobacillus brevis</i>	SP 48	200
<i>Lactobacillus bulgaricus</i>	LB2	50
<i>Lactobacillus casei</i>	BGP93	300
<i>Lactobacillus crispatus</i>	SP 28	50
<i>Lactobacillus crispatus</i>	BC5	50
<i>Lactobacillus fermentum</i>	CS57	100
<i>Lactobacillus gasseri</i>	SP 33	200
<i>Lactobacillus gasseri</i>	SP 56	50
<i>Lactobacillus helveticus</i>	SP 27	100
<i>Lactobacillus lactis</i>	LL 82	100
<i>Lactobacillus paracasei</i>	101/37	200
<i>Lactobacillus paracasei</i>	BGP 2	400
<i>Lactobacillus plantarum</i>	14D	500
<i>Lactobacillus plantarum</i>	LB931	200
<i>Lactobacillus plantarum</i>	BG 112	300
<i>Lactobacillus salivarius</i>	SP 2	100
<i>Lactococcus lactis</i>	SP 38	300
<i>Pediococcus acidilactici</i>	SP 29	300
<i>Streptococcus thermophilus</i>	Z57	200
<i>Streptococcus thermophilus</i>	SP 4	400
		*1 Billion = 10 ⁹ CFU

Each of the names of the products, ideas, brands, trademarks and logos mentioned in this document, however presented (i.e. displaying the ® or TM symbol, written in bold or large print, etc.), are either property of Sacco, owned by an affiliate or covered by a licensing agreement.

What is presented in this document as a trademark may not be such in your specific country, notwithstanding the potential presence of the ® symbol, due to national registration regulations and processes. This information is intended for business to business and Healthcare professionals' communication for specific ingredients for food, beverage, and supplement producers. The statements and information contained herein are not intended for final consumers of finished products. Any claims made for consumers remains the sole responsibility of the marketer of the finished product. This information is provided "as is" and its use is at the recipient's sole discretion and risk. These statements and the products of this company are not intended to diagnose, treat, cure or prevent any disease.

Services and Solutions

Made for you

Within the microbiome innovation space, Sacco System emerges as a reliable all-in-one partner. We specialize in handling the intricacies of manufacturing and science, freeing you to concentrate on your core business. Our range of services covers expertise in aerobic and anaerobic strains, Probiotics, Postbiotics, and Microbial Therapeutics, providing versatile solutions tailored to your unique requirements.

Process development & fermentation: from initial development to scale up:




Media screening
and optimization



Analytical method development,
qualification and validation



Molecular biology
& genetic analysis



Cell bank preparation and validation
(RCB, MCB and WCB)



Process development
and scale up



Lyophilization



Possible production in GMP
from clinical to industrial
scale (200L to 20,000L)



Stability studies

Product formulation: Our business development team can support the design of the final concept, from the definition of the scientific rationale to the selection of the most appropriate pharmaceutical form to shortcut your entry into the market.

In vitro and in vivo trials: Defining the experimental design and characterizing your product in vitro or through clinical trials.

Market Expansion: Market analysis, distributor scouting and management, connection to third-party service providers as laboratories, contract manufacturing organizations and authorities.

Regulatory Support: Registration support, new biotherapeutic dossier.

Molecular biology & laboratory analysis: Several wet labs and in silico assays to better characterize your products.

Company

Sacco system heritage in Lactic Acid Bacteria (LAB) traces its roots back to 1948, when Dr. Leo Vesely founded Centro Sperimentale del latte, a pioneer company dedicated in studying of bacteria for human health and children's nutrition.

Today we are the international biotech hub for food, nutraceutical, and pharmaceutical industries. Operating in over 110 countries worldwide, Sacco System provides its expertise on probiotic products development and offer science based proprietary strains and customized blends, supporting consumer needs.

Our innovative approach covers production, research and development in nutraceutical and pharmaceutical fields, having available three pilot plants, cutting edge technologies and two facilities GMP Pharmaceutical certified. An expertise extends beyond LAB, following the evolving demands of the market. This includes the development, process validation and commercial production of probiotics, postbiotics, Next-Generation bacteria (obligate aerobes and anaerobes strains) and biotherapeutics (BPs).

Quality


Our quality system is extensive and as a confirmation of our strong commitment to quality, Sacco System has achieved the main certifications over the years.



Contact us to discover our solution!

 info@saccosystem.com

 **SACCO SYSTEM**

 **SACCO SYSTEM**
Via Alessandro Manzoni, 29/A,
22071 Cadorago CO, Italy

rev 01/24